Drugs / XG005
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04067947 | Jul → Dec 2019 | — | Xgene Pharmaceutical Group | Completed | No outcome recorded |
| Phase 1 | NCT04499209 | Oct 2017 → Jan 2018 | — | Xgene Pharmaceutical Group | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | XG005 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04499209 ↗ |
| Route | Oral | “four ascending single and multiple oral doses of XG005” NCT04067947 ↗ |